Focused On-demand Library for Mitochondrial import inner membrane translocase subunit TIM50

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q3ZCQ8

UPID:

TIM50_HUMAN

Alternative names:

Alternative UPACC:

Q3ZCQ8; Q330K1; Q6QA00; Q96FJ5; Q96GY2; Q9H370

Background:

Mitochondrial import inner membrane translocase subunit TIM50 plays a pivotal role in protein translocation across the mitochondrial inner membrane. It is an essential component of the TIM23 complex, facilitating the movement of transit peptide-containing proteins. TIM50 also exhibits phosphatase activity in vitro, which underscores its biochemical versatility.

Therapeutic significance:

Linked to 3-methylglutaconic aciduria 9, a genetic disorder marked by early-onset seizures and developmental delays, TIM50's genetic variants underscore its clinical relevance. Understanding the role of Mitochondrial import inner membrane translocase subunit TIM50 could open doors to potential therapeutic strategies.